Received 29 October 2018 Revised 17 January 2019 Accepted 21 January 2019 DOI 101002agm212051 R E V I E W A R T I C L E Polypharmacy elderly cancer patients Challenges way clinical pharmacists contribute resourcelimited settings Sunil Shrestha12 Sudip Shrestha3 Saval Khanal2 1Department Pharmacy Nepal Cancer Hospital Research Center Lalitpur Nepal 2Nepal Health Research Innovation Foundation Lalitpur Nepal 3Department Medical Oncology Nepal Cancer Hospital Research Center Lalitpur Nepal Correspondence Sunil Shrestha Department Pharmacy Nepal Cancer Hospital Research Center Harisiddhi Lalitpur Nepal Email sunilcrestagmailcom Abstract The aim study address problems associated polypharmacy elderly cancer patients highlight role pharmacists cases sourcelimited settings A narrative review existing literature performed summarize evidence impact polypharmacy elderly cancer pa tients pharmaceutical strategies manage This review emphasizes significance polypharmacy ignored real clinical practice Polypharmacy elderly cancer population mainly chemotherapy neoplastic agents cancer treatment treatment adverse drug actions neoplastic agents patients comorbid conditions drug interac tions The role clinical pharmacist specialized oncology hospitals oncology departments tertiary care hospitals established case developing countries A clinical pharmacist contribute solving problems associated polypharmacy identifying risks associated polypharmacy management resourcelimited settings As devel oped countries involvement clinical pharmacist cancer care elderly patients play vital role recognition management polypharmacy related problems Further research conducted support role K E Y W O R D S cancer care elderly patients polypharmacy resourcelimited settings role pharmacists 1 I NTRO D U C TI O N difficult avoid35 With background aimed summarize existing evidence impact polypharmacy elderly Aging associated multipleoften chronicillnesses cancer patients We aimed provide strategies clinical creased risk prescription multiple medicines The use nu pharmacists contribute management problems merous medicationsgenerally described polypharmacycan lead unfortunate conditions medications known interact other12 Elderly patients likely experience poly pharmacy compared age groups tend suffer 2 P O LY PH A R M AC Y therapeutic conditions requiring pharmacotherapy Polypharmacy With regards definition polypharmacy contention elderly individuals poses significant risk wellbeing standard meaning term Be term This open access article terms Creative Commons AttributionNonCommercialNoDerivs License permits use distribution medium provided original work properly cited use noncommercial modifications adaptations 2019 The Authors Aging Medicine published Beijing Hospital John Wiley Sons Australia Ltd 42 wileyonlinelibrarycomjournalagm2 Aging Med 201924249 43 polypharmacy characterized multiple points view As indicated Hajjar et al6 polypharmacy characterized use multiple medications andor administration medica medicationconnected events usually prescribed extensive number medicines disease supportive care13 tions clinically indicated representing unnecessary drug The treatment cancer involves multiple medications use Polypharmacy comprises number medications taken patient existence wrong medications cludes unfavorable impactsreactions cytotoxic treat ments14 Usage multiple medicines important factor prescription amalgamation increase risk treating health conditions elderly people compli adverse drug events ADEs underutilization medication repetition medicine6 Polypharmacy defined use cations arise antineoplastic therapy influence consequences cancer treatment1 multiple drugs medically necessary veloping concern senior adults7 Because relationship The practice medicines prompt additional drugs medication regimen different medications prescribed antagonistic medication responses falls term polypharmacy respond problems medicines especially negative connotations range adverse events officially powerless geriatric populace8 valid case cytotoxic chemotherapy management malignancy There numerous ADRs ranging mild nausea Polypharmacy mild severe issue patients age group particularly elderly patients For instance existence comorbidities elderly cancer patients drug therapies combined furthermore expanded ac cessibility overthecounter herbal complementaryalterna tive medicines patients fail declare specialist doctor pharmacist contribute polypharmacy These pop ulations remain high risk ADEs linked polypharmacy myelosuppression anticancer agents prompt polypharmacy14 31 Prevalence polypharmacy elderly cancer patients The reported prevalence polypharmacy elderly population varies substantially ranging 10 9615 Due changes drugdrug interactions DDIs Elderly patients undergo phys pharmacokinetic profile associated aging elderly patients iologic changes modify different pharmacokinetics pa varied pharmacodynamic responses medications The comorbid rameters absorption firstpass metabolism protein binding distribution metabolism eliminations drugs Molecular condition aging leads higher prevalence polypharmacy elderly population younger patients16 Therefore cellular fluctuations modify pharmacodynamics group likely suffer ADEs decreased therapeu tabolism drug variations alter effect drug ticbeneficial effects medications Elderly cancer patients target site narrow therapeutic windows related che motherapeutic agents drugs given910 Together alterations pharmacokinetic pharmacodynamic vari ables risk elderly patients increased adverse drug reactions ADRs exposed chemotherapy radiotherapy chem otherapeutic agents lead acute longterm toxicity require supportive medications This result drug interactions increased drug burden17 Balducci et al1 examined numerous studies elderly cancer patients showed age risk factor polypharmacy interrupt consequence cancer treatment Similarly Jørgensen et al18 reported 35 el 3 P O LY PH A R M AC Y I N E LD E R LY C A N C E R PATI E NT S derly patients diagnosed breast lung colon rectal prostate ovarian cancer taking drugs 1996 2006 They prevalence polypharmacy increased Among elderly cancer patients polypharmacy noteworthy age 39 8090yearold patients 41 9091yearold consequence incidence increasing Nevertheless pre patients Polypharmacy common older cancer pa dominance impacts disease patients defined particularly endoflife scenes11 Globally numerous elderly tients compared younger cancer patients age group cancer Surprisingly increase cer patients comorbidities treated prescribed drugs initiated 6 months manifes drugs oncology hospitals clinics In man tations malignant growth demonstrating increase trend agement cancers chemotherapy combination prescription drugs period treatments common single chemotherapy agents The A study conducted ambulatory cancer patients Canada sug inception chemotherapy cytotoxic targeted gested newly diagnosed cancer patients aged 60 years agent drugs management growth manifesta tions harmful impacts identified treatment result polypharmacy12 Prescribing drug chemotherapeutic agents foremost challenges treating elderly cancer patients fur polypharmacy assessed taking average med ications time diagnosis13 A Scottish study assessed com munitydispensed prescription adverse event data 1995 2010 revealed number dispensed medications significant forecaster potentially DDIs19 Nobili et al20 thermore simple Cancers patients great risk supported previous findings concluded elderly SHRESTHA ET Al 44 population constitutes largest group people highly susceptible assessment polypharmacy factor predispose adverse developing DDIs Besides aforementioned studies evidence supports higher prevalence polypharmacy elderly popu lation For example retrospective crosssectional study conducted Goh et al17 evaluated types incidence drugrelated prob actions furthermore interventions polypharmacy uncertain There urgent need consistent interventions manage poly pharmacy geriatric oncology practice15 In prospective study elderly cancer patients aged 70 years geriatricians proposed change prescribed medications lems elderly cancer patients showed nonadherence switching chemotherapy supportive care underprescribing ADEs Drugrelated problems identified 776 elderly cancer patients approximately incidence 20 patients based CGA results proposed medi cation intervention benefits reported32 drugrelated problems patient Polypharmacy leading In contrast prospective cohort study conducted Kalsi et al33 drugrelated problems prevalent elderly cancer patients receiving outpatient intravenous chemotherapy17 Prithviraj et al21 conducted showed association geriatricianled CGA interventions improved chemotherapy tolerance geriatric patients aged crosssectional study showing high prevalence polypharmacy 70 chemotherapy The intervention applied inappropriate medication newly diagnosed elderly cancer patients Another prospective observational studyby Flood et al22 showed unnecessary medications adjustment antihypertensive medications undertreated patients 19 polypharmacy common elderly cancer patients hos dertreated patients benefited pitalization oncologyacute care unit elderly Aparicio et al34 conducted pilot study assess viability Thus elderly cancer patients higher risk polypharmacy mini geriatric assessment MGA gastroenterologist patients age cancer showed adaptation nononcological therapy social care 32 Polypharmacy association outcomes geriatric oncology MGA 72 38 patients respectively Yet difference strategy suggested MGA help gastroenterologists adaptation treatment cancer An intervention study Sokol et al10 oncol Polypharmacy associated major problem risk hos ogists required change prescriptions based possible pitalization death elderly patients cer2327 The review study conducted 2016 associated multiple risks factors adverse outcomes geriatric oncology result polypharmacy15 In oncology setting polypharmacy drug interactions physicians edit prescrip tions unrelated potential drug interactions The study concluded physicians consider possible outcomes association polypharmacy chronic use data Incentives pro appropriate medications contribute patients worsened vided physicians optimization safe effective oncologic condition frailty syndrome poor physical function poor survival higher number comorbidities2830 Some studies aimed associate polypharmacy outcomes geriatric oncology example 2014 Kim et al31 considered group patients aged therapeutics A 2012 interventional study Horgan et al35 assessing CGA provides recommendations modification medication geri atric oncology patients aged 70 years This intervention led 65 years underwent comprehensive geriatric assess identification previously unidentified medical problems ment CGA palliative firstline chemotherapy cancer 70 patients sites involved Out 98 patients 40 patients met Corcoran et al36 suggested reducing risks associated criteria polypharmacy The result observed polypharmacy educating patients physicians drug monitor nection early termination palliative chemotherapy ing intervention Additionally investigations pharmaco The current evidence advocates increase kinetic parameters chemotherapeutic agents provide information number medications geriatric cancer patients possible drug interactions adverse outcomes decide high risk chemotherapyinduced toxicity adverse physiologi toxicity levels prevent pharmacological responses cal functions Some prominent ADRs associated chemo drug interactions therapies defective blood counts immunosuppression nausea Finally intervention study involving multidisciplinary team vomiting hair loss renal toxicity hepatotoxicity Lastly including clinical pharmacists enrolled highrisk geriatric patients tervention screening polypharmacy regular clinical practice require precise studies scrutinize impact polyphar macy outcomes geriatric cancer patients15 polypharmacy showed effective reduction unneces sary medications resulting improved patient health outcomes7 33 Interventions polypharmacy geriatric assessment studies 4 R I S K S A N D PRO B LE M S A S S O C I ATE D W ITH P O LY PH A R M AC Y To extent polypharmacy aligned evalua There unfavorable results related polypharmacy tion studies geriatric oncology settings However regrettable unavoidable These include ADRs SHRESTHA ET Al drug interactions prolonged hospitalization increased hospital stay increase cost health care 41 Adverse drug reactions 45 polypharmacy DDIs ADRs repeated hospital admission demonstrated researchers4648 ADEs increase health care costs increasing hospital admissions result unpre dicted drug interaction1449 increased visits emer gency department clinics50 The burden polypharmacy increases greater cost health care Polypharmacy associated increased cost1 increasing It connected elevated risk ADEs elderly patients medical expenses patient health care institution greater possibility DDIs medication adherence vulner Increased health care costs include price unsuitable iden ability elderly populace sideeffects medications tical medications additional medicines treating newly induced physical changes identified aging trigger difficulties taking medicines proposed3738 Runciman et al39 affirmed ADEs symptoms laboratory costs supplementary patient monitoring obligatory12 accountable 30 unexpected hospital admissions In Swedish study Hovstadius et al51 increases pre people aged 75 years Australian health care settings scription medication spending 62 73 patients taking 42 Drug interactions The frequency drug interactions elderly patients docu 10 medications respectively Shrestha et al14 discuss financial burden patients ADRs chemotherapy ADRs seen patients aged 60 years In retrospective cohort study Akazawa et al52 mented Senior patients greatest risk having drugrelated showed association polypharmacy increased risk taking teractions kinds drug interactions happen including drugdrug drugdisease drugfood drugalcohol drugherbalprod possibly unsuitable medicines increased hospital admissions leading increments medical costs approximately 3052 ucts drugnutritionalstatus interaction The variables including agerelated physiologic alterations pharmacokinetics pharma codyanmics infirmity interindividual variability decreased homoeo static mechanisms human body psychosocial concerns universal patients progressive life threatening diseases considered drug interactions evaluated40 One important challenges elderly patients cancer drug interaction inescapable41 Polypharmacy drug interactions recognized hazardous factors ADR common outcomes42 This reason multiple visits emer gency department43 The threat polypharmacy plus DDI greater elderly individuals regularly experience ill effects variety therapeutic conditions prescribed multiple medications connected liver undesirable impacts Ruiter et al44 ADRs DDIs 5 M A N AG E M E NT O F P O LY PH A R M AC Y BY C LI N I C A L PH A R M AC I S T S I N E LD E R LY C A N C E R PATI E NT S Polypharmacy problem requires rational organized method Incorporating clinical pharmacy services multidiscipli nary oncology team play crucial role identification risks accompanying polypharmacy management polypharmacy53 There strategies managing polypharmacy elderly cer patients applicable chronic diseases 51 Taking appropriate medication history Evaluating relevance patients present drug therapy increased risk hospitalization fourfold patients aged 75 compared aged 55 74 years Alkan et al45 guidance forthcoming treatment selections obtained appropriate medication history This obtained close 445 elderly cancer patients nearly onethird teamwork health professionals patients doctors nurses exposed potentially inappropriate medications drug interac clinical pharmacists cooperation patients Existing tions severe In study investigators procedures intended documenting drug histories polypharmacy drugs inpatient status diagnosis lung cancer connected severe drug interac identified insufficient needing improvement cases actually hazardous54 Health professionals consolidate tions This study carried Turkey suggests cli medical records date A thorough medication nicians restrained prescribing preparing drugs elderly patients Girre et al41 conducted study France history includes interview questions currently prescribed drugs doses routes administration frequencies 105 patients half interactions treatment duration medications overthecounter herbal moderate 43 Increased health care cost Another possible issue accompanies polypharmacy increased health care cost direct indirect An association remedies complementaryalternative medicines assessment drug containers lists communication commu nity pharmacies specific doctors Additionally information history previous medical reports obtained earlier prescriptions previous drug interactions aforemen tioned ADRs previous hypersensitivity reactions55 One SHRESTHA ET Al 46 important responsibilities clinical pharmacists obtain accurate medication histories abovedescribed methods 54 Patientcentered medication therapy confirm patients present forthcoming therapy harm The service given clinical pharmacist patientcentered effective 52 Medication reconciliation medication review medication therapy management developing treatment plan concentrates intention associated patients medication Recently medication therapy management extended important initiative largely need en hance patients medication treatment62 Most prolonged disease According St Peter56 individual procedures required avoid conditions cancer require patients persist treatment resolve medicationrelated complications subsequently indefinitely asymptomatic order meet therapeutic reduce polypharmacy These include parameters medica objectives For improvement patients healthrelated results tion reconciliation medication review ongoing patientcentered medication therapy management56 A multidisciplinary approach certain pharmacistmanaged medication therapy programs maintained63 This help lower health care cost involving clinical pharmacists medical oncology group ef patients fectively manage polypharmacy elderly cancer patients This era information technology hospitals Medication reconciliation medication review im linked technology enhance care perative tools pharmaceutical care The terms different patients Online software checking DDIs diminish require definition Medication reconciliation straightfor ward management drugs57 method building list correct medications58 Medication reconciliation preliminary DDIs According Beers Criteria record elderly patients aware possibility wrong medication administered Regulatory authorities focus distri medication review A critical involvement addressing polypharmacy sys tematic detailed medication review evaluate patient obtained therapeutic advantage medication continuing medical needs risks sideeffects balanced probable pros59 The patients medica bution appropriate medications prescriptions elderly patients support safer alternatives64 55 Pharmacovigilance center When comes treatment cancer patients age tion regimen assessed safety correctness group ADRs documented universally perspective specific patients multiple morbid illnesses health unavoidable constituents management ADRs normal literacy issues sociodemographics Advanced clinical drug expectable Once ADRs identified ADR alert stickers therapy expertise necessary medication review recognized pharmacists clinical skill sets60 notes mentioning ADRs placed patients medical file This help future alert concerned physicians65 Medication reconciliation medication review potentially Additionally information circulated patients involve prescription deprescription drugs Similar decent related doctors practices standards ought connected medical treat ment started discontinued61 In global scenario health care deprescribing impartially innovative 56 Drug information center theory way decreasing halting medications The drug information center play vital role elderly cancer aimed minimizing multiple uses drugs improving health patients providing information polypharmacy ADEs It comes patients 53 Multidisciplinary approach help management polypharmacy The pharmacist provide information elderly patients different categories general information diseases medications prescribed medicine works body possi In cases polypharmacy managed multidiscipli ble sideeffects interactions duration treatments nary approach The study Holland conducted Irish teach Elderly patients need information drugs dispensed ing hospital demonstrates interdisciplinary teamwork prescribed clinical pharmacist doctor develop comprehensive ness accurateness discharge medicines estab lishment discharge medication reconciliation service commanded pharmacist57 Shrestha et al53 stated 57 Educational intervention awareness polypharmacy clinical pharmacist act bridge medical Educational intervention awareness shape patients cologist patient oncology setting providing clinical titudes polypharmacy Numerous elderly patients strug pharmacy services These services discharge medication gle deal issues health care Limited health literacy reconciliation best provided clinical pharmacist exaggerates struggles creates greater diversity SHRESTHA ET Al 47 adverse health activities consequences elderly patients O R C I D The effect lack health literacy lives elderly populace requires greater consideration understanding community services practice66 An elderly populace little health literacy increased risk nonadherence unintentional medication experience adverse events Whittaker et al67 rec ommend educational involvement build familiarity poison inhibition means medication safety strategies older adults low wellbeing proficiency Numerous approaches educational intervention awareness patients polypharmacy elderly patients audiovisual activities presentations brochures understandable local languages Raising physicians awareness ventures support higher experts respect polypharmacy noxious ef fects drug interactions result healthier outcomes el derly patients 6 CO N C LU S I O N Sunil Shrestha httpsorcidorg0000000291747120 Saval Khanal httpsorcidorg0000000152010612 R E F E R E N C E S 1 Balducci L GoetzParten D Steinman MA Polypharmacy management older cancer patient Ann Oncol 201324suppl 7vii36vii40 2 Jørgensen TL Hallas J Land LH Herrstedt J Comorbidity poly pharmacy elderly cancer patients significance treatment outcome tolerance J Geriatr Oncol 20101287102 3 Jörgensen T Johansson S Kennerfalk A Wallander MA Svardsudd K Prescription drug use diagnoses healthcare utilization elderly Ann Pharmacother 200135910041009 4 Lapi F Pozzi C Mazzaglia G et al Epidemiology suboptimal prescribing older community dwellers twowave popula tionbased survey Dicomano Italy Drugs Aging 20092612 10291038 5 Fitzgerald LS Hanlon JT Shelton PS et al Reliability modified medication appropriateness index ambulatory older persons Ann Pharmacother 1997315543548 This review successfully discussed challenges associated 6 Hajjar ER Cafiero AC Hanlon JT Polypharmacy elderly patients polypharmacy elderly cancer patients ways pharmacists contribute managing problems low middleincome settings Polypharmacy elderly cancer patients important growing public health issues grave concern associated management cancer medical oncologists clinicians poly pharmacy related negative health outcomes The clinical pharmacist major role play selecting best interven tions needed enhance suitable polypharmacy consequently managing problems associated polypharmacy properly ac complish better clinical results patients AC K N OW L E D G M E N T S The authors like gratefully acknowledge Dr Subish Palaian Associate Professor Pharmacy Practice Gulf Medical University Ms Krisha Danekhu active member Nepal Health Research Innovation Foundation C O N FL I C T O F I N T E R E S T The authors declare conflicts exist work AU T H O R C O N T R I B U T I O N S Sunil Shrestha conceptualized idea manuscript wrote initial version manuscript Sudip Shrestha added content manuscript revised substantially Saval Khanal added ideas content initial version helped substantially improving manuscript stages manuscript writing All authors read approved final manuscript Am J Geriatr Pharmacother 200754345351 7 Maher RL Hanlon J Hajjar ER Clinical consequences polyphar macy elderly Expert Opin Drug Saf 20141315765 8 Zia A Kamaruzzaman SB Tan MP Polypharmacy falls older people balancing evidencebased medicine falls risk Postgrad Med 20151273330337 9 TamMcDevitt J Polypharmacy aging cancer Oncology 200822910521055 discussion 1055 1058 1060 10 Sokol KC Knudsen JF Li MM Polypharmacy older oncology pa tients need interdisciplinary approach sideeffect management J Clin Pharm Ther 2007322169175 11 LeBlanc TW McNeil MJ Kamal AH Currow DC Abernethy AP Polypharmacy patients advanced cancer role medication discontinuation Lancet Oncol 2015167e333e341 12 Lees J Chan A Polypharmacy elderly patients cer clinical implications management Lancet Oncol 2011 121312491257 13 Puts MT CostaLima B Monette J et al Medication problems older newly diagnosed cancer patients Canada common A prospective pilot study Drugs Aging 2009266519536 14 Shrestha S Shakya R Shrestha S Shakya S Adverse drug reaction cancer chemotherapy financial burden different hospitals Nepal Int J Pharmacovigilance 20172117 15 Sharma M Loh KP Nightingale G Mohile SG Holmes HM Polypharmacy potentially inappropriate medication use geri atric oncology J Geriatr Oncol 201675346353 16 Mangoni AA Jackson SH Agerelated changes pharmacokinetics pharmacodynamics basic principles practical applications Br J Clin Pharmacol 2004571614 17 Goh I Lai O Chew L Prevalence risk polypharmacy elderly cancer patients receiving chemotherapy ambulatory cology setting Curr Oncol Rep 201820538 18 Jørgensen TL Hallas J Friis S Herrstedt J Comorbidity elderly cancer patients relation overall cancerspecific mortality Br J Cancer 2012106713531360 19 Guthrie B Makubate B HernandezSantiago V Dreischulte T The rising tide polypharmacy drugdrug interactions population database analysis 19952010 BMC Med 201513174 20 Nobili A Pasina L Tettamanti M et al Potentially severe drug teractions elderly outpatients results observational study SHRESTHA ET Al 48 administrative prescription database J Clin Pharm Ther 2009344377386 21 Prithviraj GK Koroukian S Margevicius S Berger NA Bagai R Owusu C Patient characteristics associated polypharmacy inappropriate prescribing medications older adults cancer J Geriatr Oncol 201233228237 22 Flood KL Carroll MB Le CV Brown CJ Polypharmacy hospital ized older adult cancer patients experience prospective observational study oncologyacute care elders unit Am J Geriatr Pharmacother 200973151158 23 Badgwell B Stanley J Chang GJ et al Comprehensive geriatric sessment risk factors associated adverse outcomes source utilization cancer patients undergoing abdominal surgery J Surg Oncol 20131083182186 24 Freyer G Geay JF Touzet S et al Comprehensive geriatric assess ment predicts tolerance chemotherapy survival elderly patients advanced ovarian carcinoma GINECO study Ann Oncol 2005161117951800 25 Hamaker ME Seynaeve C Wymenga AN et al Baseline compre hensive geriatric assessment associated toxicity survival elderly metastatic breast cancer patients receiving singleagent chemotherapy results OMEGA study Dutch breast cancer trialists group Breast 20142318187 40 Mallet L Spinewine A Huang A The challenge managing drug interactions elderly people Lancet 20073709582185191 41 Girre V Arkoub H Puts MTE et al Potential drug interac elderly cancer patients Crit Rev Oncol Hematol tions 2011783220226 42 Obreli Neto PR Nobili A Lyra DP Jr et al Incidence predic tors adverse drug reactions caused drugdrug interactions elderly outpatients prospective cohort study J Pharm Pharm Sci 2012152332343 43 Dookeeram D Bidaisee S Paul JF et al Polypharmacy poten tial drugdrug interactions emergency department patients Caribbean Int J Clin Pharm 201739511191127 44 Ruiter R Visser LE Rodenburg EM Trifiro G Ziere G Stricker BH Adverse drug reactionrelated hospitalizations persons aged 55 years populationbased study Netherlands Drugs Aging 2012293225232 45 Alkan A Yasar A Karci E et al Severe drug interactions po tentially inappropriate medication usage elderly cancer patients Support Care Cancer 2017251229236 46 Becker ML Kallewaard M Caspers PW Visser LE Leufkens HG Stricker BH Hospitalisations emergency department visits drugdrug interactions literature review Pharmacoepidemiol Drug Saf 2007166641651 26 Jyrkka J Enlund H Korhonen MJ Sulkava R Hartikainen S Polypharmacy status indicator mortality elderly pop ulation Drugs Aging 2009261210391048 47 Larson EB Kukull WA Buchner D Reifler BV Adverse drug reac tions associated global cognitive impairment elderly sons Ann Intern Med 19871072169173 27 Sganga F Landi F Ruggiero C et al Polypharmacy health comes older adults discharged hospital results CRIME study Geriatr Gerontol Int 2015152141146 48 Spaniolas K Cheng JD Gestring ML Sangosanya A Stassen NA Bankey PE Ground level falls associated significant mor tality elderly patients J Trauma 2010694821825 28 Nightingale G Hajjar E Swartz K AndrelSendecki J Chapman A Evaluation pharmacistled medication assessment iden tify prevalence associations polypharmacy poten tially inappropriate medication use ambulatory senior adults cancer J Clin Oncol 2015331314531459 29 Turner JP Shakib S Singhal N et al Prevalence factors associ ated polypharmacy older people cancer Support Care Cancer 201422717271734 30 Elliot K Tooze JA Geller R et al The prognostic importance polypharmacy older adults treated acute myelogenous leuke mia AML Leuk Res 2014381011841190 31 Kim JW Kim YJ Lee KW et al The early discontinuation pal liative chemotherapy older patients cancer Support Care Cancer 2014223773781 32 Caillet P CanouiPoitrine F Vouriot J et al Comprehensive geriatric assessment decisionmaking process elderly patients cancer ELCAPA study J Clin Oncol 2011292736363642 33 Kalsi T BabicIllman G Ross PJ et al The impact comprehensive geriatric assessment interventions tolerance chemotherapy older people Br J Cancer 2015112914351444 34 Aparicio T Girard L Bouarioua N Patry C Legrain S Soule JC A mini geriatric assessment helps treatment decision elderly pa tients digestive cancer A pilot study Crit Rev Oncol Hematol 20117716369 35 Horgan AM Leighl NB Coate L et al Impact feasibility comprehensive geriatric assessment oncology setting pilot study Am J Clin Oncol 2012354322328 36 Corcoran ME Polypharmacy older patient cancer Cancer Control 199745419428 37 Gallagher P Barry P OMahony D Inappropriate prescribing elderly J Clin Pharm Ther 2007322113121 38 Brager R Sloand E The spectrum polypharmacy Nurse Pract 20053064450 39 Runciman WB Roughead EE Semple SJ Adams RJ Adverse drug events medication errors Australia Int J Qual Health Care 200315suppl 1i49i59 49 Onder G Pedone C Landi F et al Adverse drug reactions cause hospital admissions results Italian Group Pharmacoepidemiology Elderly GIFA J Am Geriatr Soc 2002501219621968 50 Bourgeois FT Shannon MW Valim C Mandl KD Adverse drug events outpatient setting 11year national analysis Pharmacoepidemiol Drug Saf 2010199901910 51 Hovstadius B Petersson G The impact increasing polypharmacy prescribed drug expenditurea registerbased study Sweden 20052009 Health Policy 20131092166174 52 Akazawa M Imai H Igarashi A Tsutani K Potentially inappro priate medication use elderly Japanese patients Am J Geriatr Pharmacother 201082146160 53 Shrestha S Shrestha S Palaian S Can clinical pharmacists bridge gap medical oncologists patients resourcelim ited oncology settings An experience Nepal published online ahead print January 1 2018 J Oncol Pharm Prac httpsdoi org1011771078155218784734 54 Cornish PL Knowles SR Marchesano R et al Unintended medi cation discrepancies time hospital admission Arch Intern Med 20051654424429 55 FitzGerald RJ Medication errors importance accurate drug history Br J Clin Pharmacol 2009676671675 56 St Peter WL Management polypharmacy dialysis patients Semin Dial 2015284427432 57 Holland DM Interdisciplinary collaboration provision pharmacistled discharge medication reconciliation service Irish teaching hospital Int J Clin Pharm 2015372310319 58 St Peter WL Improving medication safety chronic kidney disease patients dialysis medication reconciliation Adv Chronic Kidney Dis 2010175413419 59 Payne RA Avery AJ Polypharmacy greatest pre general practice Br J Gen Pract scribing challenges 2011615838384 60 Pai AB Cardone KE Manley HJ et al Medication recon dialysisdependent therapy management ciliation SHRESTHA ET Al patients need systematic approach Clin J Am Soc Nephrol 201381119881999 61 Scott IA Hilmer SN Reeve E et al Reducing inappropriate polyphar macy process deprescribing JAMA Intern Med 20151755 827834 62 Farinde A Benefits medication therapy management trauma care J Trauma Nurs 2014215228 63 MurphyMenezes M Role pharmacist medication ther apy management services patients osteoporosis Clin Ther 201537715731586 64 Fialova D Topinkova E Gambassi G et al Potentially inappropriate medication use elderly home care patients Europe JAMA 20052931113481358 65 Shrestha S Shrestha S Khanal S Establishment cancer hospitalbased pharmacovigilance center Nepal Res Social Adm Pharm 2018141110881089 49 66 Findley A Low health literacy older adults meanings prob lems recommendations social work Soc Work Health Care 20155416581 67 Whittaker CF Tom SE Bivens A KleinSchwartz W Evaluation educational intervention knowledge awareness med ication safety older adults low health literacy Am J Health Educ 2017482100107 How cite article Shrestha S Shrestha S Khanal S Polypharmacy elderly cancer patients Challenges way clinical pharmacists contribute resourcelimited settings Aging Med 201924249 httpsdoiorg101002agm212051 SHRESTHA ET Al